skip to primary navigationskip to content
 

CEGX: The spinout that’s measuring the epigenome to improve human health

Cambridge Enterprise will be holding a series of departmental Roadshow events showcasing some of the most prominent research that has spun out of the university.
When Sep 12, 2017 06:00 PM to
Oct 12, 2017 08:00 PM
Where Pfizer Lecture Theatre, Department of Chemistry, Lensfield Road
Add event to calendar vCal
iCal

These events will provide a networking opportunity to meet like-minded people with an interest in entrepreneurship and is open to academics, postdocs and PhDs alike from across all departments at the University.

On 12 September, hear Dr Jason Mellad, Chief Executive Officer (CEO) at Cambridge Epigenetix, give a talk about the company’s route to commercialisation and how the relationship with Cambridge Enterprise was able to support this journey.

Cambridge Epigenetix, a pioneer in the development of epigenetic sequencing, was founded in 2012 by Prof Shankar Balasubramanian of the Department of Chemistry.

The company is focused on developing best-in-class tools to make studying DNA methylation and DNA hydroxymethylation as easy as studying DNA sequencing.

Further information and details on how to register can be found here.

OPdA Tweets

Upcoming events

CEGX: The spinout that’s measuring the epigenome to improve human health

Sep 12, 2017

Pfizer Lecture Theatre, Department of Chemistry, Lensfield Road

Pitching Training Event

Sep 15, 2017

Seminar Room B, 17 Mill Lane

Upcoming events

RSS Feed Latest news

Grants available through the Returning Carers Scheme - apply by 29 September

Aug 16, 2017

The Returning Carers Scheme provides funds to support career development following a career break or a period of leave for caring responsibilities.

Opportunity to apply for up to £30,000 funding from the EPSRC: apply by 16 August

Aug 08, 2017

Postdocs are invited to apply via the OPdA for funding for activities which fall under the remit of the EPSRC and the Global Challenges Research Fund.

View all news